Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Pharmacoepidemiology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1445324

Rhabdomyolysis associated with concomitant use of Colchicine and Statins in the real world: Identifying the likelihood of drug-drug interactions through the FDA adverse event reporting system

Provisionally accepted
Sha Zhang Sha Zhang 1Ming-Ming Yan Ming-Ming Yan 2*HUI ZHAO HUI ZHAO 2Xiaoyan Qiu Xiaoyan Qiu 2*Deqiu Zhu Deqiu Zhu 1*
  • 1 Department of Pharmacy, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China
  • 2 Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China

The final, formatted version of the article will be published soon.

    Background: Currently, there remains substantial controversy in research regarding whether the concomitant use of colchicine and statins increases the occurrence of rhabdomyolysis, warranting further substantiation.Objective: This study aimed to identify the likelihood drug-drug interactions (DDIs) for the co-administration of colchicine and statins resulting in rhabdomyolysis.A disproportionality analysis was conducted by using data sourced from the US Food and Drug Administration Adverse Event Reporting System (FAERS) to detect rhabdomyolysis signals associated with the combined use of colchicine and statins. The association between (colchicine/statins/colchicine and statins) and rhabdomyolysis were evaluated using information component (IC). DDI signals were calculated based on the Ω shrinkage measure and Bayesian confidence propagation neural network (BCPNN) method. Furthermore, stratification was performed based on colchicine and individual statins agents.In total, 11,119 reports of rhabdomyolysis were identified in the FAERS database, 255(2.29%) involved both colchicine and statins. Our analysis showed potential DDI signals of rhabdomyolysis (Ω025=1.17) among individuals concurrent use of colchicine and statins. Moreover, further drug-specific analysis suggests DDI signals in the colchicine-atorvastatin pair (Ω025=1.12), and colchicine-rosuvastatin pair (Ω025=1.05), along with a higher proportion of rhabdomyolysis (IC025=5.20) and (IC025=4.26), respectively.The findings suggest that concomitant use of colchicine and statins may increase the risk of rhabdomyolysis, particularly when combined with atorvastatin or rosuvastatin. Therefore, healthcare professionals should pay special attention to life-threatening AE such as rhabdomyolysis, when co-prescribing colchicine statins.

    Keywords: Colchicine, Statins, Rhabdomyolysis, drug-drug interactions, Pharmacovigilance

    Received: 07 Jun 2024; Accepted: 30 Aug 2024.

    Copyright: © 2024 Zhang, Yan, ZHAO, Qiu and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Ming-Ming Yan, Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China
    Xiaoyan Qiu, Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China
    Deqiu Zhu, Department of Pharmacy, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.